
    
      This a phase III study in which women participants with RH and Coombs negative will receive
      only one dose of 1500 IU anti-Rh immunoglobulin intramuscularly up to 72 hours post
      exposition (child-birth) and will be following until six months to verification of negative
      Coombs maintenance. Safety evaluation data will include report of all adverse events
      (including type, frequency, intensity, seriousness, severity and action taken related to the
      investigational product).
    
  